AU Patent

AU2020204418A1 — Benzoxazepin oxazolidinone compounds and methods of use

Assigned to F Hoffmann La Roche AG · Expires 2020-07-23 · 6y expired

What this patent protects

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide 5 3 kinase (PI3K) modulation activity or function having the Formula I structure: H R1 N a I H2 N AO R2 o or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the…

USPTO Abstract

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide 5 3 kinase (PI3K) modulation activity or function having the Formula I structure: H R1 N a I H2 N AO R2 o or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of t0 using such P13K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon P13K dysregulation. 105

Drugs covered by this patent

Patent Metadata

Patent number
AU2020204418A1
Jurisdiction
AU
Classification
—
Expires
2020-07-23
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.